Skip to content

NBP

NovaBridge Biosciences

NASDAQ · Healthcare · Biotechnology · US

$1.30
+3.17%
Ask drillr

Year over year

Reported trailing growth

Revenue
—
EBITDA
+52.4%
EBIT
+50.9%
EPS
+19.6%
Free cash flow
—
Operating cash flow
—

Forward estimates

Based on analyst estimates

Revenue
—
EBITDA
—
EPS
—

Three-year CAGR

Revenue
—
EBITDA
+96.6%
EBIT
+96.4%
Net income
+95.9%
EPS
+96.4%
Free cash flow
+94.6%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026